London, UK - 27 April 2021: Oxford Biomedica plc ( Oxford Biomedica , the Company or the Group ) (LSE:OXB), a leading gene and cell therapy group, gives notice that copies of the 2020 Annual report and accounts and the Notice of Annual General Meeting ( AGM ) have been sent to shareholders. These documents are available on the Investors section of the Group s website at www.oxb.com . Oxford Biomedica plc announced its preliminary results for the year ended 31 December 2020 on 15 April 2021. Copies of these documents have been submitted to the Financial Conduct Authority for publication through the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
I am truly proud of the Group s achievements over the period. We not only secured major new partnerships, brought the Oxbox manufacturing facility online in record time and responded to the challenges of the pandemic, but the team has also been able to rapidly work with AstraZeneca to provide a vaccine solution for COVID-19. This is a true testament to the world-class calibre and dedication of our staff in the year that the Group also gained entry to the FTSE250. Looking to the future, with the continued tide of growth in cell and gene therapy, coupled with the Group s leadership position in the lentiviral vector field, we are well positioned to advance both our own proprietary pipeline and that of our current and future partners programmes.